These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 26383226)

  • 1. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.
    Dumont J; Euwart D; Mei B; Estes S; Kshirsagar R
    Crit Rev Biotechnol; 2016 Dec; 36(6):1110-1122. PubMed ID: 26383226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a novel cell line, CHO-MK, derived from Chinese hamster ovary tissues for biologics manufacturing.
    Masuda K; Kubota M; Nakazawa Y; Iwama C; Watanabe K; Ishikawa N; Tanabe Y; Kono S; Tanemura H; Takahashi S; Makino T; Okumura T; Horiuchi T; Nonaka K; Murakami S; Kamihira M; Omasa T
    J Biosci Bioeng; 2024 Jun; 137(6):471-479. PubMed ID: 38472071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering protein glycosylation in CHO cells to be highly similar to murine host cells.
    Gupta S; Shah B; Fung CS; Chan PK; Wakefield DL; Kuhns S; Goudar CT; Piret JM
    Front Bioeng Biotechnol; 2023; 11():1113994. PubMed ID: 36873370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production.
    Budge JD; Knight TJ; Povey J; Roobol J; Brown IR; Singh G; Dean A; Turner S; Jaques CM; Young RJ; Racher AJ; Smales CM
    Metab Eng; 2020 Jan; 57():203-216. PubMed ID: 31805379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylation Analysis of Therapeutic Glycoproteins Produced in CHO Cells.
    Carillo S; Mittermayr S; Farrell A; Albrecht S; Bones J
    Methods Mol Biol; 2017; 1603():227-241. PubMed ID: 28493134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells.
    Baker KN; Rendall MH; Hills AE; Hoare M; Freedman RB; James DC
    Biotechnol Bioeng; 2001 May; 73(3):188-202. PubMed ID: 11257601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant glycoprotein production in human cell lines.
    Swiech K; de Freitas MC; Covas DT; Picanço-Castro V
    Methods Mol Biol; 2015; 1258():223-40. PubMed ID: 25447867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
    J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of host cell line choice on glycan profile.
    Goh JB; Ng SK
    Crit Rev Biotechnol; 2018 Sep; 38(6):851-867. PubMed ID: 29262720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation.
    Ghaderi D; Zhang M; Hurtado-Ziola N; Varki A
    Biotechnol Genet Eng Rev; 2012; 28():147-75. PubMed ID: 22616486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purity by design: Reducing impurities in bioproduction by stimulus-controlled global translational downregulation of non-product proteins.
    Bojar D; Fuhrer T; Fussenegger M
    Metab Eng; 2019 Mar; 52():110-123. PubMed ID: 30468874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line.
    Kim J; Luo H; White W; Rees W; Venkat R; Albarghouthi M
    MAbs; 2020; 12(1):1844928. PubMed ID: 33171078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives for Glyco-Engineering of Recombinant Biopharmaceuticals from Microalgae.
    Barolo L; Abbriano RM; Commault AS; George J; Kahlke T; Fabris M; Padula MP; Lopez A; Ralph PJ; Pernice M
    Cells; 2020 Mar; 9(3):. PubMed ID: 32151094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding biopharmaceutical production at single nucleotide resolution using ribosome footprint profiling.
    Tzani I; Monger C; Kelly P; Barron N; Kelly RM; Clarke C
    Curr Opin Biotechnol; 2018 Oct; 53():182-190. PubMed ID: 29471208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbial protein cell factories fight back?
    ;
    Trends Biotechnol; 2022 May; 40(5):576-590. PubMed ID: 34924209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A human expression system based on HEK293 for the stable production of recombinant erythropoietin.
    Chin CL; Goh JB; Srinivasan H; Liu KI; Gowher A; Shanmugam R; Lim HL; Choo M; Tang WQ; Tan AH; Nguyen-Khuong T; Tan MH; Ng SK
    Sci Rep; 2019 Nov; 9(1):16768. PubMed ID: 31727983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Embryonic Kidney 293 Cells: A Vehicle for Biopharmaceutical Manufacturing, Structural Biology, and Electrophysiology.
    Hu J; Han J; Li H; Zhang X; Liu LL; Chen F; Zeng B
    Cells Tissues Organs; 2018; 205(1):1-8. PubMed ID: 29393161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A convenient and general expression platform for the production of secreted proteins from human cells.
    Aydin H; Azimi FC; Cook JD; Lee JE
    J Vis Exp; 2012 Jul; (65):. PubMed ID: 22872008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable miRNA overexpression in human CAP cells: Engineering alternative production systems for advanced manufacturing of biologics using miR-136 and miR-3074.
    Weis BL; Guth N; Fischer S; Wissing S; Fradin S; Holzmann KH; Handrick R; Otte K
    Biotechnol Bioeng; 2018 Aug; 115(8):2027-2038. PubMed ID: 29665036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.